FDA (CDER)
GUIDANCE FINAL
Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs
Published: 7/14/2026Detected: 7/13/2026
Summary preview
Establishes FDA’s expectations and process for conducting formal meetings with sponsors or requestors seeking advice on Over-the-Counter (OTC) monograph drug development, regulatory strategy, and submissions.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#FDA
#CDER
#formal meeting
#OTC monograph drug
#regulatory strategy
Official Source Document Source Verified
Access the original document directly from FDA CDER.
More from FDA (CDER)
- E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers (R1): Guidance for Industry10/30/2026
- Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle10/20/2026
- Regulatory Considerations for Prescription Drug Use-Related Software10/20/2026
- Safety Reporting Requirements for INDs and BA/BE Studies: Guidance for Industry and Investigators10/19/2026
- Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers10/9/2026